NOVEL APPROACH IN ANAPLASTIC CARCINOMA OF THYROID –IS THERE LIGHT AT THE END OF THE TUNNEL?

Dr. Rachana Prasad, Dr. Vishal U S Rao

Abstract


BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a rare, lethal type of thyroid cancer. The paucity of data has eluded the formation of
standardised treatment protocols. A multi-modality approach is adopted and for patients desiring aggressive treatment, radical surgery along with
chemoradiation is advocated. Patients with metastatic ATC are encouraged to participate in clinical trials as no definitive treatment is available.
CASE SUMMARY: We present a case of an elderly patient who presented in an advanced stage of ATC with distant metastasis. The patient
received the entire gamut of treatment available and responded well. The patient was decannulated and no longer PEG-tube dependent.
CONCLUSION: Though treatment for ATC remains an enigma but the novel treatments offers a ray of hope in this disease with historically
miserable prognosis.


Keywords


Anaplastic carcinoma, Thyroid cancer, Cyberknife in thyroid cancer, Metronomic therapy in thyroid cancer,

Full Text:

PDF

References


Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. SeminSurgOncol 1999;16:64-9.

McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028–34.

Pasieka JL. Anaplastic thyroid cancer. Current Opinion in Oncology

;15:78–83.

Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321–30.

Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. European Journal of Surgical Oncology 2001;27:260–4.

Akaishi J, Sugino K, Kitagawa W, Nagahama M, Ka- meyama K, Shimizu K, Ito K 2011 Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid car- cinoma. Thyroid 21:1183–1189.

X.S. Sun, S.R. Sun, N. Guevara, N. Fakhry, P.Y. Marcy, S. Lassalle, I. Peyrottes, R.J. Bensadoun, A. Lacout, J. Santini, L. Cals, J.F. Bosset, A.S. Garden, J. Thariat, Chemoradiation in anaplastic thyroid carcinomas, Critical Reviews in Oncology/Hematology, Volume 86, Issue 3, 2013, Pages 290-301

Robert C. Smallridge, Kenneth B. Ain, Sylvia L. Asa, Keith C. Bible, James D. Brierley, Kenneth D. Burman, Electron Kebebew, Nancy Y. Lee, Yuri E. Nikiforov, M. Sara Rosenthal, Manisha H. Shah, Ashok R. Shaha, and R. Michael Tuttle for the American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. Thyroid. November 2012, 22(11): 1104-1139

Smallridge RC, Copland JA 2010 Anaplastic thyroid carci- noma: pathogenesis and emerging therapies. ClinOncol 22:486–497.

Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombo- spondin 1, a mediator of the antiangiogenic effects of low- dose metronomic chemotherapy. ProcNatlAcadSci U S A 2003;100:12917–22.

Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibi- tion of neovascularization by thrombospondin-1. Nat Med 2000;6:41–8.

Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cy- clophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patient. Cancer ImmunolImmunother2006;56:641–8.

Rozados VR, Mainetti LE, Rico MJ, ZacaríasFluck MF, Matar P, Scharovsky OG. Antiangiogenic and inmunomodulatory effect of the metronomic therapy with cyclophosphamide [abstract]. Biocell2007;3:119.

Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia. 2014;16:84–96. [PMC free article] [PubMed]

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, et al. Metronomic chemotherapy: Possible clinical application in advanced hepatocellular carcinoma. TranslOncol. 2013;6:511–9. [PMC free article] [PubMed]

Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY, Pfister DG 2011 Concurrent doxorubicin and radiotherapy for ana- plastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 101:425–430.

Iagaru A, McDougall IR. F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer. ClinNucl Med 2007;32:13–5

Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, Milano MT (2009) Stereotactic body radiotherapy for treatment of adrenal metastases. Int J RadiatOncolBiolPhys 75(1):71–75

Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future oncology. 2011 Jan;7(1):145-51.

Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348–54.

Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. British Journal of Cancer 2002;86:1848–53.

Nutting CM, Convery DJ, Cosgrove VP, et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiotherapy and Oncology 2001;60:173–80.

Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control. 2011 Apr 1;18(2):89-95.

Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT. A multiinstitutional phase 2 trial of pazopanibmonotherapy in advanced anaplastic thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2012 Sep 1;97(9):3179-84.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Science translational medicine. 2013 Jan 2;5(166):166ra3-.


Refbacks

  • There are currently no refbacks.